Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy

被引:25
|
作者
Bonsang-Kitzis, Helene [1 ,6 ,7 ]
Chaltier, Leonor [2 ]
Belin, Lisa [2 ]
Savignoni, Alexia [2 ]
Rouzier, Roman [1 ]
Sablin, Marie-Paule [3 ]
Lerebours, Florence [3 ]
Bidard, Francois-Clement [3 ]
Cottu, Paul [3 ]
Sastre-Garau, Xavier [4 ]
Lae, Marick [4 ]
Pierga, Jean-Yves [3 ,5 ]
Reyal, Fabien [1 ,6 ,7 ]
机构
[1] Inst Curie, Dept Surg, Paris, France
[2] Inst Curie, Dept Biostat, Paris, France
[3] Inst Curie, Dept Med Oncol, Paris, France
[4] Inst Curie, Dept Tumor Biol, Paris, France
[5] Paris Descartes Univ, Paris, France
[6] Inst Curie, Translat Res Dept, Residual Tumor & Response Treatment Lab, Paris, France
[7] INSERM, Immun & Canc UMR932, Paris, France
来源
PLOS ONE | 2015年 / 10卷 / 12期
关键词
PROGESTERONE-RECEPTOR; ESTROGEN-RECEPTOR; PREOPERATIVE CHEMOTHERAPY; ADJUVANT CHEMOTHERAPY; MOLECULAR SUBTYPES; DOSE INTENSITY; OBESE-PATIENTS; TUMOR SIZE; EXPRESSION; SURVIVAL;
D O I
10.1371/journal.pone.0144359
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background Triple-negative breast cancers (TNBC) are a specific subtype of breast cancers with a particularly poor prognosis. However, it is a very heterogeneous subgroup in terms of clinical behavior and sensitivity to systemic treatments. Thus, the identification of risk factors specifically associated with those tumors still represents a major challenge. A therapeutic strategy increasingly used for TNBC patients is neoadjuvant chemotherapy (NAC). Only a subset of patients achieves a pathologic complete response (pCR) after NAC and have a better outcome than patients with residual disease. Purpose The aim of this study is to identify clinical factors associated with the metastatic-free survival in TNBC patients who received NAC. Methods We analyzed 326 cT1-3N1-3M0 patients with ductal infiltrating TNBC treated by NAC. The survival analysis was performed using a Cox proportional hazard model to determine clinical features associated with prognosis on the whole TNBC dataset. In addition, we built a recursive partitioning tree in order to identify additional clinical features associated with prognosis in specific subgroups of TNBC patients. Results We identified the lymph node involvement after NAC as the only clinical feature significantly associated with a poor prognosis using a Cox multivariate model (HR = 3.89 [2.42-6.25], p<0.0001). Using our recursive partitioning tree, we were able to distinguish 5 subgroups of TNBC patients with different prognosis. For patients without lymph node involvement after NAC, obesity was significantly associated with a poor prognosis (HR = 2.64 [1.28-5.55]). As for patients with lymph node involvement after NAC, the pre-menopausal status in grade III tumors was associated with poor prognosis (HR = 9.68 [5.71-18.31]). Conclusion This study demonstrates that axillary lymph node status after NAC is the major prognostic factor for triple-negative breast cancers. Moreover, we identified body mass index and menopausal status as two other promising prognostic factors in this breast cancer subgroup. Using these clinical factors, we were able to classify TNBC patients in 5 subgroups, for which pre-menopausal patients with grade III tumors and lymph node involvement after NAC have the worse prognosis.
引用
收藏
页数:15
相关论文
共 50 条
  • [1] Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy (vol 10, e0144359, 2015)
    Bonsang-Kitzis, Helene
    Chaltier, Leonor
    Belin, Lisa
    Savignoni, Alexia
    Rouzier, Roman
    Hamy, Anne-Sophie
    Sablin, Marie-Paule
    Lerebours, Florence
    Bidard, Francois-Clement
    Cottu, Paul
    Sastre-Garau, Xavier
    Lae, Marick
    Pierga, Jean-Yves
    Reyal, Fabien
    [J]. PLOS ONE, 2016, 11 (07):
  • [2] Triple-negative breast cancer with extracapsular extension of axillary lymph node metastasis: Prognostic value.
    Maksimovic, S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [3] Axillary Lymph Node Response after Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
    Qureshi, I.
    Samiian, L.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2010, 17 : S50 - S50
  • [4] Association of Triple-negative Breast Cancer with Extracapsular Extension of Axillary Lymph Node Metastasis
    Maksimovic, S.
    Jakovljevic, B.
    Gojkovic, Z.
    [J]. EUROPEAN JOURNAL OF CANCER, 2012, 48 : S150 - S150
  • [5] Association of triple-negative breast cancer with extracapsular extension of axillary lymph node metastasis
    Maksimovic, S.
    Jakovljevic, B.
    [J]. BREAST, 2011, 20 : S78 - S78
  • [6] Analysis of risk factors of axillary lymph-node metastasis in triple-negative breast cancer
    Jin, Jie
    Liu, Peng-fei
    Ye, Jian-dong
    Wu, Yun-yun
    [J]. ASIAN JOURNAL OF SURGERY, 2023, 46 (05) : 2265 - 2267
  • [7] The Role of Axillary Lymph Node Residual Cancer Burden in the Survival of Triple Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
    Khoury, Thaer
    Attwood, Kristopher
    Gandhi, Shipra
    [J]. LABORATORY INVESTIGATION, 2023, 103 (03) : S155 - S155
  • [8] Prognostic impact of axillary lymph node status after neoadjuvant chemotherapy for patients with breast cancer
    Nakamura, R.
    Yamamoto, N.
    Miyaki, T.
    Itami, M.
    [J]. CANCER RESEARCH, 2019, 79 (04)
  • [9] Adjuvant Capecitabine after Neoadjuvant Chemotherapy in Triple Negative Breast Cancer with Lymph Node Metastasis
    Oner, Irem
    Turkel, Alper
    Karacin, Cengiz
    Seyran, Erdogan
    Tolunay, Pinar Kubilay
    Oksuzoglu, Omur Berna Cakmak
    [J]. JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2023, 33 (09): : 1012 - 1018
  • [10] Efficacy and prognostic factors of neoadjuvant chemotherapy for triple-negative breast cancer
    Feng Ding
    Ru-Yue Chen
    Jun Hou
    Jing Guo
    Tian-Yi Dong
    [J]. World Journal of Clinical Cases, 2022, 10 (12) : 3698 - 3708